The development of unpredictable vaginal bleeding is one of the main reasons for the discontinuation of treatment in users of continuous combined hormone replacement therapy (HRT). There is no accurate method of predicting which women will develop bleeding on this regimen. The aim of this study was to determine whether sonographic assessment of the endometrium could be used as a predictor of bleeding after the commencement of this treatment. Sonographic measurements of the endometrium were performed before treatment and then every 3 months for 1 year. Measurements of the endometrium were taken in both the transverse and sagittal planes and a record of the frequency of bleeding was maintained. Pretreatment measurements tended to be greater in those who developed bleeding within 1 month of the commencement of treatment, but the difference in measurements between those who developed bleeding and those who did not was not statistically significant. Endometrial thickness tended to be greater at 3, 6, 9 and 12 months of treatment in those who had bleeding compared with those who did not, but again the difference was not statistically significant. It is concluded that whilst bleeding on continuous combined HRT is more common in women with a thicker endometrium, sonographic assessment of the endometrium is not an accurate enough predictor of bleeding to be used in this clinical setting.

Keywords:
Menopause, Hormone replacement therapy, Ultrasound, Endometrium
This content is only available via PDF.
© 1997 S. Karger AG, Basel
1997
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.